Imcivree

Generic name: setmelanotide

Used for: Weight loss in acquired hypothalamic obesity · Weight loss in Bardet-Biedl syndrome · Weight loss in POMC, PCSK1 or LEPR deficiency (genetic) · 2 more

How do you pay?

How to pay the least

Ask for the cash price

Imcivree

We didn’t find one.

  1. Ask your pharmacy for Imcivree’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameImcivree
Authorized genericsetmelanotide
Regular genericsetmelanotide
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Imcivree?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Imcivree’s maker. Ask the pharmacy for Imcivree’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Imcivree itself, from the same company, sold without the brand name, and usually for less. For now Imcivree is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Imcivree’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged:

  • 4 years and older with acquired hypothalamic obsesity (HO).
  • 2 years and older with Bardet-Biedl syndrome (BBS).
  • 2 years and older with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by an genetic test demonstrating variants in POMC, PCSK1, or LEPRgenes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

Limitations of Use:

IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:

  • Obesity due to suspected POMC, PCSK1, or LEPR-deficiency with POMC, PCSK1, or LEPRvariants classified as benign or likely benign.
  • Other types of obesity not related to acquired HO, BBS or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

Source: the FDA label for Imcivree (Rhythm Pharmaceuticals, Inc), April 1, 2026. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/imcivree/